Editorial commentary: Prophylactic echinocandin: is there a subgroup of intensive care unit patients who benefit?

Affiliations

¹ The National Aspergillosis Centre, University Hospital of South Manchester, The University of Manchester, Manchester Academic Health Science Centre, United Kingdom.

Editorial

Eavan G Muldoon et al. Clin Infect Dis. 2014 May.

. 2014 May;58(9):1227-9.

doi: 10.1093/cid/ciu080. Epub 2014 Feb 18.

¹ The National Aspergillosis Centre, University Hospital of South Manchester, The University of Manchester, Manchester Academic Health Science Centre, United Kingdom.

No abstract available

Keywords: anidulafungin; candidaemia; caspofungin; micafungin; peritonitis.

Comment on

MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting.
Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, Schuster M, Judson MA, Revankar SG, Caeiro JP, Mangino JE, Mushatt D, Bedimo R, Freifeld A, Nguyen MH, Kauffman CA, Dismukes WE, Westfall AO, Deerman JB, Wood C, Sobel JD, Pappas PG. Ostrosky-Zeichner L, et al. Clin Infect Dis. 2014 May;58(9):1219-26. doi: 10.1093/cid/ciu074. Epub 2014 Feb 18. Clin Infect Dis. 2014. PMID: 24550378 Clinical Trial.